McKesson Corporation $MCK Stock: Calamos Wealth Management LLC Boosts Stake

Calamos Wealth Management LLC grew its stake in shares of McKesson Corporation (NYSE:MCK) by 27.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,835 shares of the company’s stock after purchasing an additional 1,489 shares during the quarter. Calamos Wealth Management LLC’s holdings in McKesson were worth $5,836,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in MCK. Nvwm LLC boosted its holdings in shares of McKesson by 933.3% in the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 28 shares during the last quarter. Delos Wealth Advisors LLC acquired a new position in McKesson during the second quarter worth $27,000. Trellis Wealth Advisors LLC acquired a new position in McKesson during the third quarter worth $32,000. GK Wealth Management LLC bought a new stake in McKesson during the third quarter worth $38,000. Finally, Curry Webb Wealth Management LLC bought a new stake in McKesson during the third quarter worth $38,000. Institutional investors own 85.07% of the company’s stock.

Insider Activity

In other McKesson news, EVP Francisco Fraga sold 650 shares of McKesson stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total value of $716,924.00. Following the completion of the sale, the executive vice president owned 4,414 shares in the company, valued at $4,868,465.44. The trade was a 12.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 2,462 shares of company stock valued at $2,511,106. 0.06% of the stock is owned by company insiders.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Analyst Upgrades and Downgrades

MCK has been the topic of several recent analyst reports. Leerink Partners boosted their price objective on shares of McKesson from $1,070.00 to $1,200.00 and gave the stock an “outperform” rating in a research note on Thursday. Royal Bank Of Canada raised their target price on shares of McKesson from $845.00 to $965.00 and gave the company a “sector perform” rating in a research note on Thursday. Barclays lifted their price target on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th. Morgan Stanley set a $977.00 price objective on McKesson in a research report on Tuesday, October 6th. Finally, Robert W. Baird set a $1,015.00 target price on McKesson in a research note on Thursday, August 6th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,026.18.

McKesson Stock Down 1.0%

Shares of McKesson stock traded down $11.21 on Friday, hitting $1,060.79. The stock had a trading volume of 812,129 shares, compared to its average volume of 691,239. The stock has a market cap of $123.68 billion, a price-to-earnings ratio of 27.28, a price-to-earnings-growth ratio of 1.99 and a beta of 0.27. McKesson Corporation has a twelve month low of $723.68 and a twelve month high of $1,121.50. The business’s 50 day moving average is $938.13 and its two-hundred day moving average is $868.12.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, topping the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The business had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. During the same period last year, the firm posted $9.86 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. As a group, equities analysts predict that McKesson Corporation will post 45.26 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is currently 9.67%.

McKesson Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.